Adaptimmune Therapeutics PLC Annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD from 2013 to 2023
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
-
Summary
-
Adaptimmune Therapeutics PLC quarterly/annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from 2013 to 2023.
- Adaptimmune Therapeutics PLC Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending June 30, 2024 was $70M.
- Adaptimmune Therapeutics PLC Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the twelve months ending June 30, 2024 was -$71.4M, a 19.1% increase year-over-year.
- Adaptimmune Therapeutics PLC annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was -$113M, a 30.9% increase from 2022.
- Adaptimmune Therapeutics PLC annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2022 was -$163M, a 3.6% decline from 2021.
- Adaptimmune Therapeutics PLC annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2021 was -$157M, a 21.1% decline from 2020.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Annual (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Annual Growth (%)